Essex Bio-Technology (1061 HK)

Essex Bio-Technology is a biopharmaceutical company that develops, manufactures, and commercializes genetically engineered therapeutic fibroblast growth factors (FGF) and other biopharmaceutical products. Its products primarily treat wound healing and diseases in ophthalmology and dermatology, including the Beifushu series for eye injuries and the Beifuji series for surface wounds. The company is headquartered in Hong Kong and was founded in 1998.